• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    /C O R R E C T I O N -- National Association of Corporate Directors/

    10/10/25 10:00:00 AM ET
    $BIIB
    $IFF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Chemicals
    Industrials
    Get the next $BIIB alert in real time by email

    In the news release, Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors, issued 10-Oct-2025 by National Association of Corporate Directors over PR Newswire, we are advised by the company that the third paragraph, the end of the last line, should read "IBM Business Transformation Services" instead of "IBM Consulting Business Transformation Services" as originally issued inadvertently. The complete, corrected release follows:

    Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors

    Seasoned executives bring deep expertise in innovation, governance, and business to strengthen NACD's leadership board excellence

    WASHINGTON, Oct. 10, 2025 /PRNewswire/ -- The National Association of Corporate Directors® (NACD®) today announced the appointment of Jesús Mantas, recently retired Global Leader of IBM Business Consulting, and Wes Bricker, Global Assurance Leader at PwC, to its board of directors, effective immediately.

    The appointments bring to NACD a wealth of experience spanning technology, innovation, assurance, governance and capital markets — further strengthening the association's ability to guide directors as they navigate today's rapidly evolving business landscape.

    Mantas serves on the boards of Biogen (NASDAQ:BIIB), where he chairs the compensation and management development committee, and International Flavors & Fragrances (NYSE:IFF), where he is on the innovation and audit committees. He is a Senior Advisor for NASDAQ, the Council for Global Competition and Innovation and IE University New York College and is vice chair of the board of HITEC. Mantas recently retired as the global leader of IBM Business Transformation Services.

    "I am honored to follow my mentor and fellow IBM senior leader Nick Donofrio as I join the NACD board," Mantas said. "As directors, we face compounding geopolitical, generational and technological disruption in the companies and communities we serve. I look forward to working with the NACD board and the broader corporate governance ecosystem to steward sustainable value creation in the global boardrooms we serve."

    Bricker brings together the combined impact of 134,000 Assurance partners and staff across the PwC network. He helps guide the development of trust, transparency and value creation for companies and investors through innovative, high-quality assurance solutions. Previously, he served as PwC U.S. vice chair and Trust Solutions co-leader, leading the firm's audit, digital assurance and tax reporting practices. Earlier, Bricker was chief accountant of the U.S. Securities and Exchange Commission. He also serves on the board of the American Institute of Certified Professional Accountants (AICPA) and as chair of the board of XBRL International.

    "NACD plays a critical role in elevating board performance and advancing trust in the capital markets," Bricker said. "I'm honored to join the NACD board and contribute to its work in strengthening governance, transparency and board-management alignment."

    Peter Gleason, president and CEO of NACD, welcomed both leaders to the board.

    "Jesús and Wes each bring exceptional insight and experience that reflect the dynamic needs of today's boards," Gleason said. "Jesús' expertise in digital transformation and innovation, combined with Wes' deep understanding of regulatory, legal and audit issues, will be invaluable as NACD continues to equip boards to lead with purpose and confidence."

    Mantas holds degrees in telecommunications and business administration from the Universidad Politécnica de Madrid and has served as an adjunct professor at the University of California Graduate School of Management and is certified in Corporate Governance by Harvard Business School. Bricker is a certified public accountant licensed in Virginia, Pennsylvania, New Jersey and the District of Columbia, and is a member of the New York State Bar Association.

    Visit the NACD Governance web page to learn more. 

    About NACD

    The National Association of Corporate Directors® (NACD®) is the leading member organization for corporate directors who want to expand their knowledge, grow their network and maximize their potential. For more than 47 years, NACD has helped boards and the business community elevate their performance and create long-term value. Our leadership continues to raise standards of excellence and advance board effectiveness at thousands of member companies.

    NACD's value insights, professional development events and resources, such as the NACD Directors Summit™ and the NACD Directorship Certification® program, support boards in navigating complex challenges. With a growing network of more than 24,000 members across more than 20 Chapters, boards are better equipped to make well-informed decisions on the critical, strategic issues facing their businesses today. Learn more at www.nacdonline.org.

    Press Contact: 

    Shannon Bernauer 

    [email protected]

    571-367-3688

    (PRNewsfoto/National Association of Corporate Directors)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/global-leaders-jesus-mantas-and-wes-bricker-join-nacd-board-of-directors-302580855.html

    SOURCE National Association of Corporate Directors

    Get the next $BIIB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BIIB
    $IFF

    CompanyDatePrice TargetRatingAnalyst
    Biogen Inc.
    $BIIB
    9/25/2025$190.00Buy
    Jefferies
    International Flavors & Fragrances Inc.
    $IFF
    9/8/2025Underperform → Peer Perform
    Wolfe Research
    International Flavors & Fragrances Inc.
    $IFF
    8/7/2025Outperform → Perform
    Oppenheimer
    Biogen Inc.
    $BIIB
    7/21/2025$142.00Hold
    Truist
    International Flavors & Fragrances Inc.
    $IFF
    6/4/2025$105.00Buy
    Tigress Financial
    International Flavors & Fragrances Inc.
    $IFF
    5/8/2025$84.00Equal Weight → Overweight
    Barclays
    Biogen Inc.
    $BIIB
    4/28/2025$118.00Buy → Hold
    HSBC Securities
    Biogen Inc.
    $BIIB
    4/4/2025Buy → Hold
    Argus
    More analyst ratings

    $BIIB
    $IFF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Biogen with a new price target

    Jefferies initiated coverage of Biogen with a rating of Buy and set a new price target of $190.00

    9/25/25 8:28:11 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Intl Flavors upgraded by Wolfe Research

    Wolfe Research upgraded Intl Flavors from Underperform to Peer Perform

    9/8/25 8:37:37 AM ET
    $IFF
    Major Chemicals
    Industrials

    Intl Flavors downgraded by Oppenheimer

    Oppenheimer downgraded Intl Flavors from Outperform to Perform

    8/7/25 7:47:58 AM ET
    $IFF
    Major Chemicals
    Industrials

    $BIIB
    $IFF
    SEC Filings

    View All

    International Flavors & Fragrances Inc. filed SEC Form 8-K: Leadership Update

    8-K - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Filer)

    8/7/25 4:31:06 PM ET
    $IFF
    Major Chemicals
    Industrials

    SEC Form 10-Q filed by International Flavors & Fragrances Inc.

    10-Q - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Filer)

    8/5/25 5:05:58 PM ET
    $IFF
    Major Chemicals
    Industrials

    International Flavors & Fragrances Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Filer)

    8/5/25 4:26:13 PM ET
    $IFF
    Major Chemicals
    Industrials

    $BIIB
    $IFF
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VUMERITY issued to BIOGEN INC

    Submission status for BIOGEN INC's drug VUMERITY (ORIG-1) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/12/2024. Application Category: NDA, Application Number: 761347, Application Classification: Type 3 - New Dosage Form

    9/16/24 6:52:10 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for VUMERITY issued to BIOGEN INC

    Submission status for BIOGEN INC's drug VUMERITY (SUPPL-17) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/11/2024. Application Category: NDA, Application Number: 211855, Application Classification: Manufacturing (CMC)

    9/16/24 6:24:32 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for VUMERITY issued to BIOGEN INC

    Submission status for BIOGEN INC's drug VUMERITY (SUPPL-15) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211855, Application Classification: Labeling

    3/25/24 4:41:37 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIIB
    $IFF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Godbout Sean converted options into 26 shares and covered exercise/tax liability with 8 shares, increasing direct ownership by 4% to 495 units (SEC Form 4)

    4 - BIOGEN INC. (0000875045) (Issuer)

    10/6/25 1:00:24 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Mantas Jesus B

    4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

    9/3/25 8:09:28 PM ET
    $IFF
    Major Chemicals
    Industrials

    SEC Form 4 filed by Director Fribourg Paul J

    4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

    9/3/25 8:09:26 PM ET
    $IFF
    Major Chemicals
    Industrials

    $BIIB
    $IFF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    /C O R R E C T I O N -- National Association of Corporate Directors/

    In the news release, Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors, issued 10-Oct-2025 by National Association of Corporate Directors over PR Newswire, we are advised by the company that the third paragraph, the end of the last line, should read "IBM Business Transformation Services" instead of "IBM Consulting Business Transformation Services" as originally issued inadvertently. The complete, corrected release follows: Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors Seasoned executives bring deep expertise in innovation, governance, and business to strengthen NACD's leadership board excellence WASHINGTON, Oct. 10, 2025 /PRNewswire/ -- Th

    10/10/25 10:00:00 AM ET
    $BIIB
    $IFF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Chemicals
    Industrials

    Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors

    Seasoned executives bring deep expertise in innovation, governance, and business to strengthen NACD's leadership board excellence WASHINGTON, Oct. 10, 2025 /PRNewswire/ -- The National Association of Corporate Directors® (NACD®) today announced the appointment of Jesús Mantas, recently retired Global Leader of IBM Business Consulting, and Wes Bricker, Global Assurance Leader at PwC, to its board of directors, effective immediately. The appointments bring to NACD a wealth of experience spanning technology, innovation, assurance, governance and capital markets — further strengthening the association's ability to guide directors as they navigate today's rapidly evolving business landscape. Mant

    10/10/25 10:00:00 AM ET
    $BIIB
    $IFF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Chemicals
    Industrials

    Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

    – An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improvements in cognition and behavior at 2 years; results contrast with minimal change in natural history – – Improvements in overall clinical status at 3 years in the open-label extension studies reported by clinicians and caregivers in 95% of patients treated with zorevunersen – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, and Biogen Inc. (NASDAQ:BIIB) today announced the presentation of longer-term follow-up analyses from the ongoing open-label extension

    10/9/25 4:30:00 PM ET
    $BIIB
    $STOK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $BIIB
    $IFF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Fribourg Paul J bought $1,001,183 worth of shares (15,450 units at $64.80) (SEC Form 4)

    4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

    8/8/25 6:49:19 PM ET
    $IFF
    Major Chemicals
    Industrials

    Chief Executive Officer Fyrwald J Erik bought $993,714 worth of shares (15,300 units at $64.95), increasing direct ownership by 25% to 77,370 units (SEC Form 4)

    4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

    8/7/25 6:59:38 PM ET
    $IFF
    Major Chemicals
    Industrials

    Director O'Byrne Kevin bought $342,240 worth of shares (4,500 units at $76.05), increasing direct ownership by 141% to 7,696 units (SEC Form 4)

    4 - INTERNATIONAL FLAVORS & FRAGRANCES INC (0000051253) (Issuer)

    5/23/25 4:46:40 PM ET
    $IFF
    Major Chemicals
    Industrials

    $BIIB
    $IFF
    Leadership Updates

    Live Leadership Updates

    View All

    /C O R R E C T I O N -- National Association of Corporate Directors/

    In the news release, Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors, issued 10-Oct-2025 by National Association of Corporate Directors over PR Newswire, we are advised by the company that the third paragraph, the end of the last line, should read "IBM Business Transformation Services" instead of "IBM Consulting Business Transformation Services" as originally issued inadvertently. The complete, corrected release follows: Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors Seasoned executives bring deep expertise in innovation, governance, and business to strengthen NACD's leadership board excellence WASHINGTON, Oct. 10, 2025 /PRNewswire/ -- Th

    10/10/25 10:00:00 AM ET
    $BIIB
    $IFF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Chemicals
    Industrials

    Global Leaders Jesús Mantas and Wes Bricker Join NACD Board of Directors

    Seasoned executives bring deep expertise in innovation, governance, and business to strengthen NACD's leadership board excellence WASHINGTON, Oct. 10, 2025 /PRNewswire/ -- The National Association of Corporate Directors® (NACD®) today announced the appointment of Jesús Mantas, recently retired Global Leader of IBM Business Consulting, and Wes Bricker, Global Assurance Leader at PwC, to its board of directors, effective immediately. The appointments bring to NACD a wealth of experience spanning technology, innovation, assurance, governance and capital markets — further strengthening the association's ability to guide directors as they navigate today's rapidly evolving business landscape. Mant

    10/10/25 10:00:00 AM ET
    $BIIB
    $IFF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Chemicals
    Industrials

    IFF Appoints Paul J. Fribourg and Jesus B. Mantas to Board of Directors

    IFF (NYSE:IFF)—a global leader in flavors, fragrances, food ingredients, health and biosciences—today announced the appointment of Paul J. Fribourg and Jesus B. Mantas to its board of directors, effective immediately. These appointments bring extensive international leadership experience, and industry and strategic insight to IFF as the company continues to advance its innovation agenda and strengthen its market position. "I am delighted that Paul and Jesus are joining the IFF board," said Kevin O'Byrne, chair of the IFF board. "They bring a strong combination of digital innovation, global market insight and operational excellence. Their experience, leadership and vision will help guide

    7/30/25 4:15:00 PM ET
    $IFF
    Major Chemicals
    Industrials

    $BIIB
    $IFF
    Financials

    Live finance-specific insights

    View All

    IFF Declares Dividend for Third Quarter 2025

    IFF (NYSE:IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on October 10, 2025 to shareholders of record as of September 29, 2025. Welcome to IFF At IFF (NYSE:IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2025 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All R

    7/30/25 4:20:00 PM ET
    $IFF
    Major Chemicals
    Industrials

    IFF to Release Second Quarter 2025 Results on Aug. 5, 2025

    IFF (NYSE:IFF) today announced that it will release its second quarter 2025 earnings results following the market close on Tuesday, Aug. 5, 2025. The management team will host a live webcast on Wednesday, Aug. 6, 2025, at 9:00 a.m. ET to discuss results and outlook with the investor community. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE:IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver g

    7/9/25 4:15:00 PM ET
    $IFF
    Major Chemicals
    Industrials

    Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

    Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)Interim Phase 1 data show children with SMA previously treated with gene therapy experienced a substantial slowing of neurodegeneration and clinically meaningful improvements in motor function following initiation of salanersenBased on these encouraging Phase 1 data, Biogen is engaging with regulators to advance salanersen to registrational stage studies, building on extensive experience in SMA CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) announced topline results from the Phase 1 study of

    6/25/25 7:30:37 AM ET
    $BIIB
    $IONS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $BIIB
    $IFF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biogen Inc.

    SC 13G/A - BIOGEN INC. (0000875045) (Subject)

    11/12/24 1:24:28 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biogen Inc.

    SC 13G/A - BIOGEN INC. (0000875045) (Subject)

    11/4/24 11:20:12 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Biogen Inc.

    SC 13G - BIOGEN INC. (0000875045) (Subject)

    10/16/24 12:11:53 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care